Health Results Based Financing Impact Evaluation 2018, Health Facility Midline Survey
Congo, Dem. Rep., 2018
Get MicrodataCreated on
Mar 22, 2021
Last modified
Mar 22, 2021
Page views
46343
964 Rifampicine+Isoniazide+Pyrazinamide (Q14_16_74)
Data file: f1_facility.dta
Overview
Valid:
168
Invalid:
41
Minimum:
0
Maximum:
4000
Type:
Discrete
Decimal:
0
Start:
6587
End:
6590
Width:
4
Range:
0 - 4000
Format:
Numeric
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| 0 | 115 |
68.5%
|
|
| 1 | 8 |
4.8%
|
|
| 6 | 1 |
0.6%
|
|
| 10 | 1 |
0.6%
|
|
| 15 | 2 |
1.2%
|
|
| 20 | 2 |
1.2%
|
|
| 28 | 20 |
11.9%
|
|
| 29 | 1 |
0.6%
|
|
| 30 | 2 |
1.2%
|
|
| 50 | 1 |
0.6%
|
|
| 80 | 1 |
0.6%
|
|
| 83 | 1 |
0.6%
|
|
| 84 | 2 |
1.2%
|
|
| 100 | 1 |
0.6%
|
|
| 250 | 1 |
0.6%
|
|
| 275 | 3 |
1.8%
|
|
| 301 | 1 |
0.6%
|
|
| 625 | 4 |
2.4%
|
|
| 4000 | 1 |
0.6%
|
|
| Sysmiss | 41 |
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.